Responses
Late-breaking abstracts
Clinical trials in-progress
799 Durable responses and immune activation with intratumoral electroporation of pIL-12 plus pembrolizumab in actively progressing anti-PD-1 refractory advanced melanoma: KEYNOTE 695 interim data
Compose a Response to This Article
Other responses
No responses have been published for this article.